Biotech Lock Up Expiration Hell Portfolio: Wave II Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock Up Expiration Hell Portfolio: Wave II

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tuck	12/16/2004 9:25:41 AM
	of 107

>>WATERTOWN, Mass.--(BUSINESS WIRE)--Dec. 16, 2004--Acusphere, Inc. (NASDAQ:ACUS - News) today announced enrollment of 300 patients in its Phase 3 clinical program for AI-700, its lead product candidate. Cumulatively enrolling 300 patients in this program before the end of 2004 had been a publicly stated goal of the Company. AI-700 is a cardiovascular drug designed to enable ultrasound to compete more effectively with nuclear stress testing, the leading procedure for detecting coronary heart disease. Currently an estimated 9.5 million procedures are performed each year in the United States for detecting coronary heart disease. The AI-700 Phase 3 clinical program includes a pilot phase for training of new clinical sites, and two simultaneous pivotal trials. More than 20 medical centers in the United States, Europe and Australia are actively enrolling in the pivotal phase of the Phase 3 program. Acusphere estimates that 600 patients in total will be required to complete enrollment in its pivotal trials, and plans to complete enrollment of these patients in the second half of 2005. "We are pleased with the continued progress we are making in enrolling patients in the AI-700 clinical trials. We are proud to have accomplished this important milestone within the timeframe we forecasted more than a year ago, and we thank the clinical investigators, patients and all members of our clinical support team for their dedication in advancing these clinical trials." commented Sherri C. Oberg, Acusphere's President and Chief Executive Officer. "Heart disease remains the number one cause of death for men and women in the United States and in many other areas of the world. We believe that AI-700 will lead to a relatively fast and inexpensive means of screening patients suspected of having heart disease. We have established a track record of consistently delivering on our important milestones in a timely manner and we remain committed to completing enrollment in our pivotal trials in the second half of 2005." << snip Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next